查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197888

胰腺和胆道支架市场 - 增长、趋势和预测 (2023-2028)

Pancreatic and Biliary Stents Market - Growth, Trends and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计胰腺和胆道支架市场在预测期内的复合年增长率为 6.05%。

COVID-19 大流行的爆发影响了全球医疗保健系统和胆道支架市场。 例如，2021 年 10 月发表在学术期刊 WJCC 上的一篇论文报导，内窥镜 ERCP 和经皮 PTC 手术与高病毒感染率相关。 因此，最初，由于感染上升、政府限制导致非紧急外科手术（包括 ERCP 和 PTC 手术）暂停，大量 COVID-19 病例影响了监测市场的增长。 然而，由于 COVID-19感染率下降以及 ERCP 和其他外科手术的恢復，预计未来几年对胆道支架的需求将增加，预计市场将在预测期内出现显着增长。

推动这一市场增长的因素包括胰腺癌和胆道疾病患病率的增加、支架和超声内镜技术的进步，以及微创手术的普及。 例如，根据Globocan 2020报告，2025年全球将有13.25万胆囊癌患者，预计到2030年将增加到15.09万，2040年将增加到19万。我来了。 胆管癌是由阻塞胆管的肿大肿瘤引起的。 因此，胆囊癌负担的增加有望推动市场增长。 同样，2022 年 8 月发表在 AHPS 杂誌上的一篇论文报导了韩国胆囊癌、肝外胆管癌和胰腺癌的高发病率和稳步上升的死亡率。 因此，预计胆囊癌的高患病率将推动对胆道支架的需求，从而推动预测期内监测市场的增长。

此外，随着消化道手术新技术的引入，如生物可吸收支架和自膨胀金属支架（SEMS），使用支架治疗胰腺和胆道疾病的应用越来越普及。 例如，2021 年 10 月，波士顿科学公司获得了美国 FDA 510(k) 许可和 CE 标誌，可以销售 Advanix 胆道塑料支架。 因此，此类产品的推出正在推动所研究市场的增长。 此外，与开放手术相比，微创手术 (MIS) 的风险较低，因此越来越受欢迎，这导致人们更喜欢 MIS 而不是传统手术，从而推动了研究市场的增长。

因此，由于胰腺癌和胆道疾病患病率的增加、支架和内窥镜技术的进步以及微创手术的日益普及，预计胰腺和胆道市场在预测期内将会增长。 然而，对与程序复杂性和严格的政府法规相关的高成本的担忧可能会在预测期内减缓所研究市场的增长。

胰腺/胆道支架市场趋势

金属胰腺和胆道支架预计在预测期内将显着增长。

金属支架是由细线製成的自膨胀网状管，插入体腔或导管以保持胆管和胰管畅通。 由于使用各种金属支架治疗各种胰腺和胆道相关疾病，如胰腺癌、胰腺/胆道渗漏和其他恶性梗阻，预计该领域将显着增长。 此外，全球范围内前列腺癌发病率的增加也大大促进了金属支架的发展。 例如，2022年ACS报告称，美国前列腺癌病例已达26.85万例，比过去三年增长了12.5%。 因此，大量的前列腺癌病例推动了对其治疗的金属支架的需求，从而推动了这一细分市场的增长。

与金属支架应用相关的不断增加的研究和临床研究也在推动这一领域的增长。 例如，2022 年 5 月发表在《科学报告》(Scientific Reports) 上的一篇论文指出，一项临床研究报告称，使用完全包裹的自膨胀金属支架成功治疗了良性胆道结构 (BBS)。 因此，这种有希望的结果导致对金属支架的需求增加，从而推动了这一领域的增长。

此外，新产品的开发和更好的技术正在加强胰腺和胆道市场。 例如，2021 年 5 月，AMG International GmbH 为其第二个完全可生物降解的金属支架 UNITY-B 启动了 CE 标誌批准，这是一种内窥镜球囊扩张可生物降解胆道支架 (BEBS)。 该产品发布的目的是增强我们的产品阵容并增加我们在市场上的影响力。

由于各种金属支架广泛用于治疗与胰腺和胆道相关的各种疾病，预计该细分市场将在未来几年显着扩大，并在整个预测期内推动市场发展。

北美预计在预测期内将显着增长。

北美正在经历强劲的增长，医疗行业成熟，前列腺癌、胰腺癌和胆囊癌等慢性病患病率上升，推动了对胰腺和胆道支架的需求。预计将显示 例如，2022 年 ACS 报告男性胰腺癌新发病例为 32.9 千例，而女性为 29.2 万例。 同样，2022 年 1 月的 CAGS 报告了加拿大胆囊癌的高患病率。 因此，北美国家胰腺癌和胆囊癌患病率上升正在刺激胰腺支架研究市场的扩张。

此外，最近的兼併、收购和合作伙伴关係进一步推动了该细分市场的增长。 例如，2021 年 5 月，库克医疗收购了 Cantel Medical，扩大了其胆道支架和其他产品组合，以服务全球客户。 因此，该地区的此类发展可能会增加对胰腺和胆道支架的需求。 同样，在 2022 年 7 月，CDC 报告称，仅在 2021 年，美国就有 450 万成年人被诊断患有慢性肝病，占该国患有该病的成年人总数的 1.8%。 当肝臟炎症阻塞胆管时，必须放置胆道支架以缓解阻塞。 这增加了对胆道支架的需求，并促进了该地区研究市场的增长。

该地区拥有发达的医疗保健行业，前列腺癌、胰腺癌和胆囊癌等慢性病发病率上升，这些疾病可能会在预测期内提振市场并实现显着增长。被认为是高风险。

胰腺和胆道支架市场的竞争对手分析

由于市场进入者的多样性，全球胰腺和胆道支架市场竞争适中。 目前，只有少数几家公司占据了相当大的市场份额。 预计在整个预测期内，几家区域性公司将进入胰腺和胆道支架市场。 这是由于患者意识水平的提高和疾病的高患病率。 市场上的主要参与者包括波士顿科学公司、库克医疗公司、CONMED 公司、奥林巴斯公司、Becton、Dickinson and Company、雅培实验室、美敦力公司、史赛克公司、泰宇医疗等。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 胰腺癌和胆道疾病增加
    • 支架和内窥镜技术的进步
    • 微创手术越来越受欢迎
  • 市场製约因素
    • 与手术相关的高成本和復杂性
    • 严格的政府法规
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品类型
    • 塑料支架
    • 金属支架
  • 通过申请
    • 良性胆道结构
    • 胆汁/胰液渗漏
    • 胰腺癌
    • 其他用途
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Boston Scientific Corporation
    • Cook Medical Inc
    • CONMED Corporation
    • Olympus Corporation
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Medtronic Plc
    • Stryker Corporation
    • Taewoong Medical Co., Ltd.
    • Endo-Flex GmbH
    • B. Braun Melsungen AG
    • Cardinal Health

第7章 市场机会与今后动向

简介目录
Product Code: 72223

The pancreatic and biliary stents market is expected to register a CAGR of 6.05%, over the forecast period.

The outbreak of the COVID-19 pandemic impacted the global healthcare system and the biliary stents market. For instance, an article published in the journal WJCC, in October 2021, reported that endoscopic ERCP and percutaneous PTC procedures were associated with high rates of viral transmission. Thus, initially, the high number of COVID-19 cases led to increased transmission of infections that led to the suspension of non-emergency surgical procedures including ERCP and PTC procedures, imposed by the government restrictions which impacted the growth of the studied market. However, in the upcoming years, it is anticipated that declining COVID-19 infection rates and the resumption of ERCP and other surgical procedures may increase the demand for the biliary stent, and thus the market is expected to witness significant growth over the forecast period.

The factors that are driving the growth of this market are an increase in the prevalence of pancreatic cancer and biliary duct diseases, technological advancements in stents and endosonographic, and the increasing popularity of minimally invasive surgery. For instance, according to the Globocan 2020 report, globally 132.5 thousand gallbladder cancer cases will be recorded in 2025, and this number is expected to increase to 150.9 thousand by 2030 and to 190 thousand by 2040. Bile duct cancer can lead to the enlargement of a tumor blocking the bile duct. Hence, the placement of a biliary stent can assist in the optimum drainage of the bile; hence, the rising burden of gallbladder cancer is expected to boost market growth. Similarly, an article published by the journal AHPS, in August 2022, reported that high incidence and mortality rates of gallbladder, extrahepatic bile duct, and pancreatic cancer are steadily increasing in Korea. Thus, a high prevalence of gallbladder cancer is expected to drive the demand for biliary stents, thereby driving the growth of the studied market over the forecast period.

Furthermore, with the introduction of new technologies for gastrointestinal surgeries such as bioabsorbable stents and self-expanding metal stents (SEMS), the use of stents for the treatment of pancreatic and biliary diseases is gaining popularity. For instance, in October 2021, Boston Scientific received the 510 (k) US FDA clearance and CE mark approval to market its Advanix biliary plastic stents. Thus, such product launches are driving the growth of the studied market. Moreover, the increasing popularity of minimally invasive surgery (MIS) due to the low risk associated with it compared to open surgeries is increasing the preference for MIS over normal surgeries and thus, fueling the growth of the studied market.

Therefore, due to the increase in the prevalence of pancreatic cancer and biliary duct diseases, technological advancements in stents and endosonography, and increasing popularity of minimally invasive surgery, the pancreatic and biliary market is anticipated to grow over the forecast period. However, the concerns regarding the high cost associated with procedural complexities, and stringent government regulations may slow down the growth of the studied market over the forecast period.

Pancreatic & Biliary Stents Market Trends

Metal Pancreatic and Biliary Stents is Expected to Witness a Significant Growth Over the Forecast Period.

Metal stents are self-expandable mesh-like tubes of thin wire which are inserted into a lumen or duct in the human body to maintain the passage open in the bile or pancreatic duct. The segment is expected to witness significant growth owing to the wide application of a range of metal stents for the treatment of various pancreatic and biliary-related diseases such as pancreatic cancer, pancreatic and biliary leaks, and other malignant obstructions. Moreover, the increase in the number of prostate cancers worldwide has significantly aided in the growth of metallic stents. For instance, in 2022 ACS, reported a 12.5% increase in prostate cancer cases in the US over the last three years reaching 268.5 thousand prostate cancer cases in 2022. Thus, the high number of prostate cancer cases is driving the demand for metallic stents for its treatment thereby driving the growth of this segment.

The increasing research and clinical studies related to applications of metallic stents are also propelling the growth of this segment. For instance, an article published by the journal Scientific Reports, in May 2022, stated that a clinical study reported the successful treatment of benign biliary structures (BBS) using fully covered self-expandable metal stents. Thus, such promising results are leading to the increasing demand for metallic stents thereby driving the growth of the segment.

Furthermore, new products and the development of better technology have bolstered the pancreatic and biliary market. For instance, in May 2021, AMG International GmbH launched the CE mark approval of their second fully biodegradable metal stent UNITY-B, which is a balloon expandable biodegradable biliary stent (BEBS) for endoscopic use. This product launch was aimed at expanding the company's product offering as well as enhancing its market presence.

Thereby, the sector is anticipated to experience significant expansion, thus driving the market throughout the forecast period, thanks to the widespread application of a variety of metal stents for the treatment of various pancreatic and biliary-related illnesses.

North America Region is Expected to Witness a Significant Growth Over the Forecast Period.

North America is expected to witness significant growth owing to the well-established healthcare industry and the rising prevalence of chronic diseases like prostate cancer, pancreatic cancer, and gall bladder cancer which is increasing the demand for pancreatic and biliary stents. For instance, ACS in 2022, reported 32.9 thousand new pancreatic cancer cases in men compared to 29.2 thousand pancreatic cancer cases in women in the United States. Similarly, CAGS in January 2022, reported the high prevalence of gallbladder cancer in Canada. As a result, the rising prevalence of pancreatic and gallbladder cancers in North American countries is fueling the expansion of the examined market for pancreatic stents.

Furthermore, the recent mergers, acquisitions, and partnerships are further driving the growth of this segment. For instance, in May 2021, Cook Medical acquired Cantel Medical to expand its biliary stent and another product portfolio to provide services to customers globally. Thus, such development in the region is likely to boost the demand for pancreatic and biliary stents. Similarly, in July 2022, CDC reported that in 2021, 4.5 million adults were diagnosed with chronic liver disease in the United States alone which contributed to 1.8% of the country's total adult population diagnosed with the disease. When liver inflammation results in bile duct blockage, a biliary stent must be implanted to relieve the obstruction. This drives up demand for biliary stents and contributes to the growth of the studied market in the region.

Thus, the region is likely to have considerable growth, boosting the market throughout the forecast period, on account of its well-established healthcare industry and the rising prevalence of chronic diseases such as prostate cancer, pancreatic cancer, and gall bladder cancer.

Pancreatic & Biliary Stents Market Competitor Analysis

The global market for pancreatic and biliary stents is moderately competitive, with a number of different market participants. Currently, only a handful of companies hold a sizable percentage of the market share. It is anticipated that several regional players would participate in the pancreatic and biliary stents market throughout the projection period. This is due to the increasing patient awareness levels and high prevalence of diseases.Some of the key players in the market are Boston Scientific Corporation, Cook Medical Inc, CONMED Corporation, Olympus Corporation, Becton, Dickinson and Company, Abbott Laboratories, Medtronic Plc, Stryker Corporation, and Taewoong Medical Co., Ltd., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in the Prevalence of Pancreatic Cancer and Biliary Duct Diseases
    • 4.2.2 Technological Advancements in Stents and Endosonography
    • 4.2.3 Increasing Popularity of Minimally Invasive Surgery
  • 4.3 Market Restraints
    • 4.3.1 High Cost and Complexity Associated with the Procedure
    • 4.3.2 Stringent Government Regulations
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Plastic Stents
    • 5.1.2 Metal Stents
  • 5.2 By Application
    • 5.2.1 Benign Biliary Structures
    • 5.2.2 Bilio-Pancreatic Leakages
    • 5.2.3 Pancreatic Cancer
    • 5.2.4 Other Applications
  • 5.3 By End Users
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Cook Medical Inc
    • 6.1.3 CONMED Corporation
    • 6.1.4 Olympus Corporation
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Medtronic Plc
    • 6.1.8 Stryker Corporation
    • 6.1.9 Taewoong Medical Co., Ltd.
    • 6.1.10 Endo-Flex GmbH
    • 6.1.11 B. Braun Melsungen AG
    • 6.1.12 Cardinal Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS